| Active Not Recruiting | A Immunogenicity and Safety Trial of the Recombinant Zoster Vaccine （CHO Cell）, LYB004 in Adults Aged 40 Years NCT07311148 | Guangzhou Patronus Biotech Co., Ltd. | Phase 2 |
| Active Not Recruiting | A Phase 2 Study to Evaluate JCXH-105, an srRNA-based Herpes Zoster Vaccine NCT06581575 | Immorna Biotherapeutics, Inc. | Phase 2 |
| Recruiting | Safety and Immunogenicity of an Investigational Herpes Zoster Vaccine (Z-1018) Compared to Shingrix® in Health NCT06569823 | Dynavax Technologies Corporation | Phase 1 / Phase 2 |
| Completed | Nudging Patients to Increase Shingles Vaccination NCT06238726 | Geisinger Clinic | N/A |
| Completed | A First-in-Human Study to Evaluate JCXH-105, an SrRNA-based Herpes Zoster Vaccine NCT05871541 | Immorna Biotherapeutics, Inc. | Phase 1 |
| Recruiting | Immunogenicity of Zoster Vaccine in Allogeneic Hematopoietic Stem Cell Transplant Recipients NCT05554068 | Loyola University | Phase 2 |
| Terminated | A Study to Learn About a Modified RNA Vaccine Against Shingles in Healthy Adults NCT05703607 | Pfizer | Phase 1 / Phase 2 |
| Recruiting | Immunogenicity of the Recombinant Zoster Vaccine in Multiple Sclerosis Patients NCT05596526 | Prof Patrice Lalive | Phase 4 |
| Active Not Recruiting | Safety and Immunogenicity of CRV-101 Vaccine for the Prevention of Herpes Zoster in Adults Aged 50 Years and O NCT05304351 | Curevo Inc | Phase 2 |
| Completed | Trial to Evaluate the Safety, Tolerability, and Immunogenicity of an Investigational Herpes Zoster Vaccine (Z- NCT05245838 | Dynavax Technologies Corporation | Phase 1 |
| Completed | Enhancing Electronic Health Systems to Decrease the Burden of Colon Cancer, Lung Cancer, Obesity, Vaccine-Prev NCT04540081 | University of California, Davis | N/A |
| Completed | Systems Biology of Zoster Vaccine NCT04047979 | Emory University | Phase 2 |
| Completed | Treatment of Chronic Postherpetic Pain With Autologous Fat Grafting - A RCT NCT04099706 | Odense University Hospital | N/A |
| Completed | Optimal Timing of Zoster Vaccine After Zoster Illness NCT02704572 | Seoul National University Hospital | N/A |
| Completed | Immune Response to Shingles Vaccination NCT02624375 | University of Washington | Phase 4 |
| Terminated | A Comparative Study of FV-100 vs. Valacyclovir for the Prevention of Post-Herpetic Neuralgia NCT02412917 | ContraVir Pharmaceuticals, Inc. | Phase 3 |
| Unknown | ZOSTAVAX in Persons Imminently Receiving Chemotherapy for Solid Organ Tumors NCT02444936 | Louis Stokes VA Medical Center | Phase 4 |
| Completed | Comparison of a Live Herpes Zoster Vaccine and a Recombinant Vaccine in 50-59 and 70-85 Year Olds NCT02114333 | University of Colorado, Denver | Phase 1 |
| Completed | Safety, Tolerability, and Immunogenicity of Zoster Vaccine Live (ZOSTAVAX™) in Healthy Adults in India (V211-0 NCT01527370 | Merck Sharp & Dohme LLC | Phase 3 |
| Completed | ZOSTAVAX™ (Zoster Vaccine Live) Long-term Effectiveness Study (V211-024) NCT01600079 | Merck Sharp & Dohme LLC | — |
| Completed | ZOSTAVAX™ Safety and Immunogenicity in Korean Adults (V211-034) NCT01556451 | Merck Sharp & Dohme LLC | Phase 4 |
| Completed | Safety and Immunogenicity of Zoster Vaccine (ZOSTAVAX™) Made With an Alternative Manufacturing Process (AMP) ( NCT01505647 | Merck Sharp & Dohme LLC | Phase 3 |
| Completed | Systems Biology of Zoster Vaccine (ZOSTAVAX®) in Young and Elderly NCT01331161 | Emory University | N/A |
| Completed | Vitamin D Supplementation And Varicella Zoster Virus Vaccine Responsiveness In Older Long-Term Care Residents NCT01262300 | University of Colorado, Denver | Phase 1 |
| Completed | A Study of FV-100 Versus Valacyclovir in Patients With Herpes Zoster NCT00900783 | Bristol-Myers Squibb | Phase 2 |
| Completed | A 2 Week Study of Topical KD7040 in the Treatment of Postherpetic Neuralgia (PHN) NCT00576108 | Kalypsys, Inc. | Phase 2 |
| Completed | Study to Evaluate the Safety and Effectiveness of Zostavax™ in Subjects 50 - 59 Years of Age (V211-022) NCT00534248 | Merck Sharp & Dohme LLC | Phase 3 |
| Completed | Bioequivalency Study of Valacyclovir Hydrochloride 1000 mg Under Fasting Conditions NCT01132729 | Roxane Laboratories | N/A |
| Completed | Bioequivalency Study of Valacyclovir Hydrochloride 1000 mg Under Fed Conditions NCT01132716 | Roxane Laboratories | N/A |
| Completed | Study of NGX-4010 for the Treatment of Postherpetic Neuralgia NCT00300222 | NeurogesX | Phase 3 |
| Completed | Study of NGX-4010 for the Treatment of Postherpetic Neuralgia NCT00115310 | NeurogesX | Phase 3 |
| Unknown | Dose-Finding Study of REN-1654 in Patients With Post-Herpetic Neuralgia NCT00099528 | Renovis | Phase 2 |
| Completed | Safety, Tolerability, and the Body's Ability to Develop Resistance to an Investigational Vaccine for Shingles NCT00109122 | Merck Sharp & Dohme LLC | Phase 2 |
| Completed | Valacyclovir in Immunocompromised Children NCT00059592 | Baylor College of Medicine | Phase 1 |
| Completed | NGX-4010 for the Treatment of Postherpetic Neuralgia NCT00061776 | NeurogesX | Phase 2 / Phase 3 |